On 4 March 2026, the Minister for Health, Jennifer Carroll MacNeill, signed new Framework Agreements on the Supply and Pricing of Medicines with the Irish Pharmaceutical Healthcare Association (IPHA) and Medicines for Ireland (MFI). The agreements set out a structured process aimed at reducing the time patients wait for access to innovative medicines.
Addressing Historical Access Delays
Irish law already requires the HSE to decide on reimbursement applications within 180 days, but an IPHA position paper in 2025 found that 86% of medicines reimbursed in 2022-2024 exceeded that timeline. The IPHA agreement includes a policy commitment to meet the statutory 180-day timeline, with a structured process aimed at achieving it by the first quarter of 2029.
Key Objectives of the Agreements
The new frameworks, which replace the 2021-2025 agreements, will remain in effect until the end of 2029. Key objectives include:
- Speeding Up Access: Implementing process reforms to ensure faster availability of innovative drugs for Irish patients.
- Supply Chain Security: Strengthening the resilience of medicine supplies to mitigate the risk of national shortages.
- Encouraging Generics and Biosimilars: Promoting the early launch of off-patent and biosimilar medicines to create financial headroom within the health service.
- Financial Sustainability: Mechanisms to manage financial risk for the State, with a joint oversight committee monitoring reimbursement timelines, access to new medicines and financial sustainability measures.
The MFI agreement also introduces tiered pricing designed to encourage the early launch of generic and biosimilar medicines after patent expiry, and a review of the Best-Value Biologics process.
Operational Realities of the 180-Day Reimbursement Goal
The landmark agreement between the Irish Pharmaceutical Healthcare Association (IPHA), Medicines for Ireland (MFI), and the state aims to streamline the pricing and reimbursement process. Most new medicines currently take longer than the statutory 180 days to be reimbursed. Meeting the target by 2029 depends on faster assessment and decision-making by the NCPE and the HSE.
To support this goal, the IPHA agreement increases the capacity of the HSE Drugs Group to process applications. For pharma manufacturers, this agreement provides a more predictable market entry timeline, but it also demands robust clinical-effectiveness data to support reimbursement applications.
Frequently Asked Questions
What is the primary goal of the new medicine pricing agreement in Ireland?
The agreement aims to reduce the time it takes for new, innovative medicines to be approved and reimbursed for Irish patients, targeting a maximum 180-day turnaround time by 2029.
Who are the key signatories to this medicine supply agreement?
The agreement is signed by the Irish state (Department of Health/HSE), the Irish Pharmaceutical Healthcare Association (IPHA representing originators), and Medicines for Ireland (MFI representing generic and biosimilar manufacturers).
How will this agreement impact drug pricing in Ireland?
The agreements introduce tiered pricing to encourage the early launch of generic and biosimilar medicines, and set up a joint oversight committee to monitor reimbursement timelines, access to new medicines and financial sustainability.
What the Agreements Mean for Companies
For companies seeking reimbursement, the 180-day commitment is supported by more capacity in the HSE Drugs Group and by a joint oversight committee that will track reimbursement timelines. Health technology assessment by the NCPE remains part of the process, so companies still need clinical and cost-effectiveness evidence to support their applications.
The MFI agreement focuses on security of supply of essential medicines and on reducing the risk of shortages. It also encourages MFI companies to apply for Irish licences and reimbursement, to reduce reliance on high-cost exempt medicinal products.
Frequently Asked Questions
What is a Health Technology Assessment (HTA) in Ireland?
An HTA is a scientific and economic evaluation performed by the NCPE to determine if a new medicine offers sufficient clinical value relative to its cost to justify funding by the HSE.
How does the agreement help prevent medicine shortages in Ireland?
The MFI agreement focuses on security of supply of essential medicines and on reducing the risk of shortages, including by encouraging companies to license and supply more medicines in Ireland.
What are biosimilar medicines and how do they impact the agreement?
Biosimilars are highly similar versions of biologic medicines that can be launched once the original medicine's patents expire. The agreement promotes their early launch to lower HSE costs, freeing up budget to fund innovative new treatments.
Correction, 2 November 2026: We added the 4 March 2026 signing date, corrected the reimbursement-delay figures and the description of the agreements' financial and supply measures, removed unsourced claims about HPRA notice periods and safety stocks, and removed two repeated sections.
